Compounds 1, 3−9, and 11 showed NF-κB inhibitory activity against the triple negative breast cancer cell line MDA-MB-231 with IC50 values ranging from 11.9 to 72.0 μM. The gene discussed is NFKB1; the disease is triple-negative breast carcinoma.